Anlon HealthcareNSE:AHCL -2.75%17 Return-on-Tangible-Equity is 18.24% as of Mar. 2026, which is 55% below its 10-year median of 40.45. GuruFocus rates NSE:AHCL with a GF Score™ of 17/100. The stock has 5 warning signs investors should review. Among 897 Drug Manufacturers companies, Anlon Healthcare ranks better than 68.45% on this metric.
Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Anlon Healthcare's annualized net income for the quarter that ended in Mar. 2026 was ₹420 Mil. Anlon Healthcare's average shareholder tangible equity for the quarter that ended in Mar. 2026 was ₹2,302 Mil. Therefore, Anlon Healthcare's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2026 was 18.24%.
The historical rank and industry rank for Anlon Healthcare's Return-on-Tangible-Equity or its related term are showing as below:
NSE:AHCL'
s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -6.93 Med: 40.45 Max: 130.37
Current: 14.27
During the past 5 years, Anlon Healthcare's highest Return-on-Tangible-Equity was 130.37%. The lowest was -6.93%. And the median was 40.45%.
NSE:AHCL's Return-on-Tangible-Equity is ranked better than 68.45% of 897
companies
in the Drug Manufacturers industry
Industry Median: 7.9
vs NSE:AHCL: 14.27
Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.
Be Aware
Net Income is used.
Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.
Anlon Healthcare Return-on-Tangible-Equity Related Terms
Anlon Healthcare Return-on-Tangible-Equity Historical Data
* Premium members only.
The historical data trend for Anlon Healthcare's Return-on-Tangible-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NSE:AHCL vs ZTS, UTHR: Return-on-Tangible-Equity Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Anlon Healthcare's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Anlon Healthcare Return-on-Tangible-Equity vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Anlon Healthcare's Return-on-Tangible-Equity distribution charts can be found below:
* The bar in red indicates where Anlon Healthcare's Return-on-Tangible-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is four times the quarterly (Mar. 2026) net income data.
Return-on-Tangible-Equity is displayed in the 10-year financial page.
What does a Return-on-Tangible-Equity of 18.24% mean?
Anlon Healthcare (NSE:AHCL) has a Return-on-Tangible-Equity of 18.24% as of Mar. 2026. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anlon Healthcare and its competitors. This is 55% below median its historical median of 40.45. According to the industry distribution chart, Anlon Healthcare ranks #283 out of 897 companies in the Drug Manufacturers industry, placing it in the top 31.5%.
Is Anlon Healthcare's Return-on-Tangible-Equity too high?
Anlon Healthcare's current Return-on-Tangible-Equity of 18.24% is 55% below median its 10-year median of 40.45. The Drug Manufacturers industry median Return-on-Tangible-Equity is 7.90. Anlon Healthcare's value of 18.24% is 130.9% above this industry median. Based on the distribution chart, Anlon Healthcare ranks #283 out of 897 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Anlon Healthcare has a GF Score™ of 17/100, reflecting its overall financial health beyond just this single metric.
How does Anlon Healthcare's Return-on-Tangible-Equity compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Anlon Healthcare ranks #283 out of 897 companies for Return-on-Tangible-Equity. This puts Anlon Healthcare in the upper half of its industry. The industry median Return-on-Tangible-Equity is 7.90. Anlon Healthcare's value of 18.24% is 130.9% above this benchmark. While the company's 10-year median is 40.45 vs. the industry median of 7.90, Anlon Healthcare has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Return-on-Tangible-Equity for a Drug Manufacturers company?
The median Return-on-Tangible-Equity among Drug Manufacturers companies is 7.90, based on 897 companies in the industry. Companies in the top quartile (top 25%) have a Return-on-Tangible-Equity significantly above this median, while those in the bottom quartile fall well below. However, Return-on-Tangible-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Anlon Healthcare's current Return-on-Tangible-Equity of 18.24% is 130.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Return-on-Tangible-Equity mean?
A high Return-on-Tangible-Equity can signal that a stock is expensive relative to its fundamentals. Return on tangible equity is the ratio of current-period net income to average two-period tangible equity. View historical data on Anlon Healthcare and its competitors. For the Drug Manufacturers industry, the median Return-on-Tangible-Equity is 7.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Anlon Healthcare's current Return-on-Tangible-Equity is 18.24%, which is 55% below median its own 10-year median of 40.45. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Anlon Healthcare stock overvalued right now?
Anlon Healthcare (NSE:AHCL) has a current Return-on-Tangible-Equity of 18.24%. The current Return-on-Tangible-Equity is 18.24%, which is 55% below median its 10-year median of 40.45 and 130.9% above the Drug Manufacturers industry median of 7.90. Anlon Healthcare's overall GF Score™ is 17/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Return-on-Tangible-Equity calculated?
Return-on-Tangible-Equity is calculated from a company's financial statements. For Anlon Healthcare (NSE:AHCL), the current Return-on-Tangible-Equity is 18.24% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Anlon Healthcare Ltd is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which serves as raw material/ key starting material in the manufacturing of active pharmaceutical ingredients; and (ii) active pharmaceutical ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula such as tablet, capsules, ointment, syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Its products spans across the family of pharmaceutical intermediates, active pharmaceutical ingredients, nutraceutical APIs and ingredients for personal care and veterinary API.
17GF Score
Get the complete analysis for NSE:AHCL
Return-on-Tangible-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:AHCL has been successfully added to your 
